Oncolytics Biotech officer buys 29,600 shares

Oncolytics Biotech Inc.'s Chief Business Officer, Andrew Aromando, bought additional company stock in the open market.

Accepted by SEC EDGAR 02/13/2026 - 07:00 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Oncolytics Biotech Inc.'s Chief Business Officer, Andrew Aromando, bought additional company stock in the open market. On February 11, 2026, he purchased 29,600 common shares of Oncolytics Biotech at a weighted average price of $0.8587 per share, increasing his direct holdings to 55,100 common shares.

Insider Trade Summary

Net Buyer: 29,600 shares

Net Buy 1 txn

Insider Aromando Andrew

Role Chief Business Officer

Bought 29,600 shs ($25K)

Increase in Position 116.1%

Type	Security	Shares	Price	Value
Purchase	Common Shares	29,600	$0.8587	$25K

Holdings After Transaction: Common Shares — 55,100 shares (Direct)

Holdings Before and After: Common Shares, 25,500 to 55,100 shares (Direct)

Other Insiders: 8 other insiders reported open-market purchases of this stock in the 30 days up to this filing.

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ONCY report for Andrew Aromando?

Andrew Aromando, Chief Business Officer of Oncolytics Biotech, reported buying 29,600 common shares. The open-market purchase occurred on February 11, 2026, and was disclosed on a Form 4 insider trading report filed with regulators.

At what price did Andrew Aromando buy ONCY shares?

He bought the ONCY common shares at a weighted average price of $0.8587. The filing notes multiple trades were executed in a price range from $0.85 to $0.86 per share during the transaction.

How many ONCY shares does Andrew Aromando own after this transaction?

Following the reported purchase, Andrew Aromando beneficially owns 55,100 ONCY common shares directly. This updated holding reflects the addition of 29,600 shares acquired in the February 11, 2026 open-market transaction.

What type of Form 4 transaction was reported for ONCY?

The Form 4 for Oncolytics Biotech (ONCY) shows an open-market purchase. The transaction code “P” indicates that 29,600 common shares were acquired in a regular market or private purchase by the company’s Chief Business Officer.

Who is the insider involved in the latest ONCY Form 4 filing?

The insider is Andrew Aromando, Chief Business Officer of Oncolytics Biotech Inc. He is an executive officer, not a director or 10% owner, and the filing reports his direct ownership of common shares after the transaction.

Were Andrew Aromando’s ONCY share purchases executed in multiple trades?

Yes. The filing states the reported price is a weighted average across multiple trades. Individual trades were executed at prices ranging from $0.85 to $0.86 per share, and detailed breakdowns are available on request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aromando Andrew

(Last) (First) (Middle)

C/O ONCOLYTICS BIOTECH INC.

4350 EXECUTIVE DRIVE, SUITE 325

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ONCOLYTICS BIOTECH INC [ ONCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/11/2026		P		29,600	A	$0.8587(1)	55,100	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.85 to $0.86, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

	/s/ Kirk Look, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.